Published January 1, 2015
| Version v1
Journal article
Open
The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder
- 1. Mersin Univ, Fac Pharm, Dept Pharmaceut Toxicol, Mersin, Turkey
- 2. Ankara Univ, Sch Med, Dept Psychiat, TR-06100 Ankara, Turkey
- 3. Kirikkale Univ, Fac Med, Dept Psychiat, Kirikkale, Turkey
- 4. Ankara Univ, Fac Pharm, Dept Toxicol, TR-06100 Ankara, Turkey
Description
What is known and objective: Genetic variations in drug-metabolizing enzyme genes change drug pharmacokinetics and response. CYP2C19 is a clinically important enzyme that metabolizes citalopram (CIT). The objective of this study was to determine CYP2C19 genetic polymorphisms and to evaluate the impact of these polymorphisms on the metabolism of citalopram in a sample of the Turkish population. We also assessed *17 polymorphism in healthy subjects in this population.
Files
bib-c669cf85-4761-432a-adb6-004b5eb5b9d1.txt
Files
(251 Bytes)
| Name | Size | Download all |
|---|---|---|
|
md5:8af07a2c57365ef2c2dfe472bb21a159
|
251 Bytes | Preview Download |